Bristol-Myers Squibb Company
BMYBristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
Drugs in Pipeline
114
Phase 3 Programs
63
Upcoming Catalysts
7
Next Catalyst
Jul 30, 2026
27dMarket Overview
Stock performance and key metrics
7 upcoming, 1 past
How BMY's past catalysts played out
Nivolumab 3 mg/kg IV
Melanoma
Entecavir (ETV)
Hepatitis B
Relatlimab
Lymphoma, Non-Hodgkin
Dasatinib
Chronic Phase Chronic Myeloid Leukemia
NKTR-214
Melanoma
Intravenous (IV) abatacept
Rheumatoid Arthritis
Indinavir sulfate
HIV Infections
Repotrectinib
Carcinoma, Non-Small-Cell Lung
Ipilimumab
Melanoma
Dacarbazine
Melanoma
Tanespimycin
Multiple Myeloma
Apremilast
Psoriasis
Muraglitazar
Diabetes Mellitus
BMS-986165
Ulcerative Colitis
KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features
Abatacept
Nephrotic Syndrome
Belatacept
Kidney Transplantation
Carboplatin
Non-Small Cell Lung Cancer
mavacamten
Hypertrophic Cardiomyopathy
Cetuximab
Squamous Cell Carcinoma of the Head and Neck
BMS-986504
Pancreatic Ductal Adenocarcinoma
docetaxel
Prostate Cancer
Pumitamig
Untreated, Unresectable, or Metastatic Colorectal Cancer
Entecavir
Chronic Hepatitis B
Peginterferon Lambda-1a
Hepatitis C Virus
cisplatin
Head and Neck Cancer
Cetuximab/Erbitux
Head and Neck Cancer
Imatinib
Chronic Phase Chronic Myeloid Leukemia
Apixaban
Deep-Vein Thrombosis
Megestrol acetate
Anorexia
Iza-bren
Non-Small Cell Lung Cancer
Topotecan
Lung Cancer
Lenalidomide
Lymphoma
Daclatasvir
Hepatitis C
Xanomeline and Trospium Chloride Capsules
Schizophrenia
Ribavirin
Hepatitis C
Nab-Paclitaxel
Non-small Cell Lung Cancer
Sofosbuvir
Hepatitis C
Pemetrexed
Non-Small Cell Lung Cancer
Adalimumab
Rheumatoid Arthritis
SAR302503
Hematopoietic Neoplasm
Prednisone
Prostatic Neoplasms
Asunaprevir
Hepatitis C Virus Infection
Gemcitabine
Urothelial Cancer
BMS-986205
Advanced Cancer
KarX-EC
Alzheimer Disease
warfarin
Atrial Fibrillation
brivanib
Advanced Non-small Cell Lung Cancer
methotrexate
Rheumatoid Arthritis
Nivolumab/rHuPH20
Melanoma
Stavudine
AIDS Dementia Complex
Nivolumab and rHuPH20
Clear Cell Renal Cell Carcinoma
Vinflunine
Bladder Cancer
Capecitabine
Breast Neoplasms
Cyclophosphamide
Relapsed or Refractory Multiple Myeloma (RRMM)
Nivolumab
Brain Neoplasms
Ozanimod
Colitis, Ulcerative
Paclitaxel
Lung Cancer
Irbesartan
Congestive Heart Failure
Deucravacitinib
Plaque Psoriasis
stavudine extended-release, lamivudine, efavirenz
HIV Infections
paclitaxel (PTX)
Breast Cancer
BMS-790052 (Daclatasvir)
Hepatitis C
Rituximab
Lymphoma
CC-97540
Lupus Erythematosus, Systemic
Ipilimumab+ Budesonide
Malignant Melanoma
relatlimab+nivolumab
Melanoma
BMS-986207
Non-Small Cell Lung Cancer
BMS-650032
Chronic Hepatitis C
Sorafenib
Hepatocellular Carcinoma
BMS-986166
Dermatitis, Atopic
BMS-823778
Diabetes Mellitus, Type 2
Pexacerfont
Major Depressive Disorder
BMS-986016
Hematologic Neoplasms
Platinum Doublet Chemotherapy
Non-Small-Cell Lung Cancer
rHuPH20
Neoplasms by Site
BMS-986177
Acute Ischemic Stroke
BMS-986158
Advanced Tumors
BMS-986278
Pulmonary Fibrosis
BMS-986408
Advanced Solid Tumors
ipilimumab (MDX-010, BMS-734016)
Melanoma
BMS-790052
Hepatitis C Infection
peg-interferon alfa-2a
Hepatitis C Virus
BMS-986178
Advanced Cancer
Anti-IP-10 Antibody
Colitis, Ulcerative
MDX-060
Hodgkin's Disease
BMS-986213
Gastric Cancer
Elotuzumab (BMS-901608; HuLuc63)
Smoldering Multiple Myeloma
BMS-770767
Dyslipidemia
Elotuzumab
Multiple Myeloma
BMS-986179
Malignant Solid Tumor
Daratumumab
Various Advanced Cancer
Cobimetinib
Advanced or Metastatic Solid Tumors
Nivolumab (BMS-936558)
Melanoma
CTLA4Ig / Abatacept
Psoriasis Vulgaris
BMS-582949
Rheumatoid Arthritis, NOS
Tyrosinase/gp100/MART-1 Peptides
Intraocular Melanoma
Luspatercept
Anemia
valacyclovir
Herpes Zoster
Trametinib
Colorectal Cancer
MDX-1100
Ulcerative Colitis
BMS-931699
Lupus
Dexamethasone
Multiple Myeloma
BMS-741672
Neuropathic Pain
Lirilumab
CANCER,NOS
BMS-817399
Rheumatoid Arthritis
BMS-690514
Breast Cancer
Ticagrelor
Coronary Artery Disease
Arlocabtagene Autoleucel
Multiple Myeloma
BMS-954561
Post-Herpetic Neuralgia (PHN)
BMS-986036
Hepatic Cirrhosis
BMS-791325
Chronic Hepatitis C
HNO Donor
Heart Failure
Cabozantinib
Advanced Renal Cell Carcinoma (RCC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nivolumab 3 mg/kg IV | Phase 3 | Melanoma | - | - |
Entecavir (ETV) | Phase 3 | Hepatitis B | - | - |
Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Dasatinib | Phase 3 | Chronic Phase Chronic Myeloid Leukemia | - | - |
NKTR-214 | Phase 3 | Melanoma | - | - |
Intravenous (IV) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Ipilimumab | Phase 3 | Melanoma | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Tanespimycin | Phase 3 | Multiple Myeloma | - | - |
Apremilast | Phase 3 | Psoriasis | - | - |
Muraglitazar | Phase 3 | Diabetes Mellitus | - | - |
BMS-986165 | Phase 3 | Ulcerative Colitis | - | - |
KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | - | - |
Abatacept | Phase 3 | Nephrotic Syndrome | - | - |
Belatacept | Phase 3 | Kidney Transplantation | - | - |
Carboplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
mavacamten | Phase 3 | Hypertrophic Cardiomyopathy | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
BMS-986504 | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
docetaxel | Phase 3 | Prostate Cancer | - | - |
Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | - | - |
Entecavir | Phase 3 | Chronic Hepatitis B | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus | - | - |
cisplatin | Phase 3 | Head and Neck Cancer | - | - |
Cetuximab/Erbitux | Phase 3 | Head and Neck Cancer | - | - |
Imatinib | Phase 3 | Chronic Phase Chronic Myeloid Leukemia | - | - |
Apixaban | Phase 3 | Deep-Vein Thrombosis | - | - |
Megestrol acetate | Phase 3 | Anorexia | - | - |
Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Topotecan | Phase 3 | Lung Cancer | - | - |
Lenalidomide | Phase 3 | Lymphoma | - | - |
Daclatasvir | Phase 3 | Hepatitis C | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Nab-Paclitaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Prednisone | Phase 3 | Prostatic Neoplasms | - | - |
Asunaprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
Gemcitabine | Phase 3 | Urothelial Cancer | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
KarX-EC | Phase 3 | Alzheimer Disease | - | - |
warfarin | Phase 3 | Atrial Fibrillation | - | - |
brivanib | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
Nivolumab/rHuPH20 | Phase 3 | Melanoma | - | - |
Stavudine | Phase 3 | AIDS Dementia Complex | - | - |
Nivolumab and rHuPH20 | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Capecitabine | Phase 3 | Breast Neoplasms | - | - |
Cyclophosphamide | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | - | - |
Nivolumab | Phase 3 | Brain Neoplasms | - | - |
Ozanimod | Phase 3 | Colitis, Ulcerative | - | - |
Paclitaxel | Phase 3 | Lung Cancer | - | - |
Irbesartan | Phase 3 | Congestive Heart Failure | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections | - | - |
paclitaxel (PTX) | Phase 3 | Breast Cancer | - | - |
BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C | - | - |
Rituximab | Phase 2 | Lymphoma | - | - |
CC-97540 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Ipilimumab+ Budesonide | Phase 2 | Malignant Melanoma | - | - |
relatlimab+nivolumab | Phase 2 | Melanoma | - | - |
BMS-986207 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-650032 | Phase 2 | Chronic Hepatitis C | - | - |
Sorafenib | Phase 2 | Hepatocellular Carcinoma | - | - |
BMS-986166 | Phase 2 | Dermatitis, Atopic | - | - |
BMS-823778 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Pexacerfont | Phase 2 | Major Depressive Disorder | - | - |
BMS-986016 | Phase 2 | Hematologic Neoplasms | - | - |
Platinum Doublet Chemotherapy | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
rHuPH20 | Phase 2 | Neoplasms by Site | - | - |
BMS-986177 | Phase 2 | Acute Ischemic Stroke | - | - |
BMS-986158 | Phase 2 | Advanced Tumors | - | - |
BMS-986278 | Phase 2 | Pulmonary Fibrosis | - | - |
BMS-986408 | Phase 2 | Advanced Solid Tumors | - | - |
ipilimumab (MDX-010, BMS-734016) | Phase 2 | Melanoma | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
peg-interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
BMS-986178 | Phase 2 | Advanced Cancer | - | - |
Anti-IP-10 Antibody | Phase 2 | Colitis, Ulcerative | - | - |
MDX-060 | Phase 2 | Hodgkin's Disease | - | - |
BMS-986213 | Phase 2 | Gastric Cancer | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 2 | Smoldering Multiple Myeloma | - | - |
BMS-770767 | Phase 2 | Dyslipidemia | - | - |
Elotuzumab | Phase 2 | Multiple Myeloma | - | - |
BMS-986179 | Phase 2 | Malignant Solid Tumor | - | - |
Daratumumab | Phase 2 | Various Advanced Cancer | - | - |
Cobimetinib | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
Nivolumab (BMS-936558) | Phase 2 | Melanoma | - | - |
CTLA4Ig / Abatacept | Phase 2 | Psoriasis Vulgaris | - | - |
BMS-582949 | Phase 2 | Rheumatoid Arthritis, NOS | - | - |
Tyrosinase/gp100/MART-1 Peptides | Phase 2 | Intraocular Melanoma | - | - |
Luspatercept | Phase 2 | Anemia | - | - |
valacyclovir | Phase 2 | Herpes Zoster | - | - |
Trametinib | Phase 2 | Colorectal Cancer | - | - |
MDX-1100 | Phase 2 | Ulcerative Colitis | - | - |
BMS-931699 | Phase 2 | Lupus | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
BMS-741672 | Phase 2 | Neuropathic Pain | - | - |
Lirilumab | Phase 2 | CANCER,NOS | - | - |
BMS-817399 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-690514 | Phase 2 | Breast Cancer | - | - |
Ticagrelor | Phase 2 | Coronary Artery Disease | - | - |
Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma | - | - |
BMS-954561 | Phase 2 | Post-Herpetic Neuralgia (PHN) | - | - |
BMS-986036 | Phase 2 | Hepatic Cirrhosis | - | - |
BMS-791325 | Phase 2 | Chronic Hepatitis C | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
Cabozantinib | Phase 2 | Advanced Renal Cell Carcinoma (RCC) | - | - |
Lymphoma
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Lupus Erythematosus, Systemic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bristol-Myers Squibb Company's drug pipeline?→
CatalystAlert tracks 114 drug candidates in Bristol-Myers Squibb Company's (BMY) pipeline across Phase 3, Phase 2. Its lead program is Nivolumab 3 mg/kg IV (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bristol-Myers Squibb Company's next FDA catalyst?→
Bristol-Myers Squibb Company's (BMY) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMY biotech catalysts?→
Add BMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bristol-Myers Squibb Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.